Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Utah Cardiology

Neither a doctor nor a teaching hospital

Research payments

$1,364,264

47 payments

Through program year 2025, Utah Cardiology is reported as receiving $1,364,264 in research payments, across 47 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $381,722 5
2024 Research $167,970 6
2023 Research $40,761 3
2022 Research $97,879 4
2021 Research $159,161 16
2020 Research $187,952 7
2019 Research $328,818 6

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,022,343 33 payments
  2. Amgen Inc. $341,921 14 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $328,046 4 payments
  2. A Study of Tirzepatide (Ly3298176) Once A Week Versus Insulin Glargine Once A Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk $326,020 6 payments
  3. FOURIER OLE (Ph 4) $229,287 5 payments
  4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $192,061 3 payments
  5. 20160250-FOURIER OLE (Ph 4) $107,429 4 payments
  6. A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine $106,486 3 payments
  7. A Phase 4 Randomized Double-Blind Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine $35,089 2 payments
  8. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $17,593 4 payments
  9. A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-To-Severe Alcohol Use Disorder (Renew-Alc-1) $9,892 1 payment
  10. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $5,672 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record